{"id":937893,"date":"2026-02-18T09:03:15","date_gmt":"2026-02-18T14:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/"},"modified":"2026-02-18T09:03:15","modified_gmt":"2026-02-18T14:03:15","slug":"vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/","title":{"rendered":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety<\/i><\/li>\n<li><i>Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner<\/i><\/li>\n<li><i>No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study<\/i><\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nVyome Holdings, Inc. (\u201cVyome\u201d) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed <i>Journal of Ophthalmic Inflammation and Infection<\/i>, a Springer-Nature journal<sup>1<\/sup>.<\/p>\n<p>\nUveitis refers to the immune-inflammation of the eye, and accounts for 10\u201315% of all cases of blindness in the developed world<sup>2<\/sup>. In the United States alone, it is associated with an estimated 30,000<sup>3<\/sup> new cases of legal blindness annually, and represents an estimated $3 billion market opportunity by 2032<sup>4<\/sup>. Topical steroids are the standard first line of treatment for uveitis. However, many patients experience inadequate response, and prolonged steroid use is associated with major complications, including cataract formation and increased pressure in the eye, leading to glaucoma.<\/p>\n<p>\nIn this publication<sup>1<\/sup>, topical eye drops of VT-1908 resulted in the desired concentration of the active drug being achieved in the eye without any irritation or signs of toxicity. VT-1908-treated eyes showed a significant reduction (<i>p<\/i>\u2009&lt;\u20090.0010) in the uveitis score with reduced lymphocyte counts in the anterior chamber compared to vehicle control. VT-1908 was found to be as effective as topical prednisone (steroid) in the preclinical model.<\/p>\n<p>\n\u201cThere remains a significant unmet need for safe and effective topically administered therapies to replace topical steroid use in the treatment of ocular inflammation. While steroids are widely used, they are associated with well-documented complications. The fact that VT-1908 was as effective as a steroid in the uveitis preclinical model and shows a very good safety profile supports its potential as an effective alternative to steroids in the eye,\u201d said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-founder of Vyome.<\/p>\n<p>\n\u201dThe publication of this paper in the peer-reviewed Springer-Nature journal underscores the scientific rigor underlying Vyome\u2019s approach to addressing inflammation in the eye. The broader addressable global market to treat inflammation in the eye is expected to exceed $20B by 2030<sup>5<\/sup>,\u201d said Venkat Nelabhotla, CEO of Vyome. \u201cBased on our pre-clinical findings, we intend to leverage the India innovation corridor to advance VT-1908 into clinical development in a very capital-efficient manner, to generate human clinical data that could result in a significant value inflection.\u201d<\/p>\n<p>\nWith no change in the capital use plan, Vyome continues to be laser-focused on the Phase 3 study of lead program, VT-1953, which is being developed for the treatment of malodor of malignant fungating wounds (MFW), a condition representing an estimated $2.2 billion<sup>6<\/sup> addressable market opportunity in the US alone, according to independent analyst Destum Partners.<\/p>\n<p><i><sup>1<\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs12348-026-00569-y&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs12348-026-00569-y&amp;index=1&amp;md5=4bea16f6d6ecb220e3f22bb8592a3f5a\">https:\/\/link.springer.com\/article\/10.1186\/s12348-026-00569-y<\/a><\/i><\/p>\n<p><i><sup>2<\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F09273948.2021.2017152&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F09273948.2021.2017152&amp;index=2&amp;md5=46f97a605794216dc3d22bbd815bc2ee\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09273948.2021.2017152<\/a><\/i><\/p>\n<p><i><sup>3<\/sup>Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect. 2018;8:6. doi: <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1186%2Fs12348-018-0148-5&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=10.1186%2Fs12348-018-0148-5&amp;index=3&amp;md5=c2b190de3d8fe88221c21fdf3068e7df\"><i>10.1186\/s12348-018-0148-5<\/i><\/a><\/p>\n<p><i><sup>4<\/sup><\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.imarcgroup.com%2Fuveitis-treatment-market&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.imarcgroup.com%2Fuveitis-treatment-market&amp;index=4&amp;md5=3e8cceeb5cffe808b7bdf22c5bbb2098\"><i>https:\/\/www.imarcgroup.com\/uveitis-treatment-market<\/i><\/a><\/p>\n<p><i><sup>5<\/sup><\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.databridgemarketresearch.com%2Freports%2Fglobal-scleritis-market&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.databridgemarketresearch.com%2Freports%2Fglobal-scleritis-market&amp;index=5&amp;md5=60469f8c3ab6b4e8ce283268b9ae9f4e\"><i>https:\/\/www.databridgemarketresearch.com\/reports\/global-scleritis-market<\/i><\/a><i \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fortunebusinessinsights.com%2Fdry-eye-syndrome-market-102413&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=Fortune+Business+Insights+%26%238211%3B+Dry+Eye+Syndrome+Market&amp;index=6&amp;md5=0172dd0f0e62a09c9986a7bb70e70b11\"><i>Fortune Business Insights \u2013 Dry Eye Syndrome Market<\/i><\/a><i \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.futuremarketinsights.com%2Freports%2Fpost-operative-cataract-surgery-inflammation-market&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.futuremarketinsights.com%2Freports%2Fpost-operative-cataract-surgery-inflammation-market&amp;index=7&amp;md5=f54a00f57c7bf67c1155eef9a426333a\"><i>https:\/\/www.futuremarketinsights.com\/reports\/post-operative-cataract-surgery-inflammation-market<\/i><\/a><i \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businessresearchinsights.com%2Fmarket-reports%2Fblepharitis-market-101447&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=Business+Research+Insights+%26%238211%3B+Blepharitis+Market+Report&amp;index=8&amp;md5=2c9ec5ce99747a26dddbe3f0bf39d193\"><i>Business Research Insights \u2013 Blepharitis Market Report<\/i><\/a><i>.<\/i><\/p>\n<p><i><sup>6<\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fapp.quotemedia.com%2Fdata%2FdownloadFiling%3FwebmasterId%3D90423%26ref%3D319729142%26type%3DPDF%26symbol%3DHIND%26cdn%3D69f2aca7026c215c37a8f7f436bb8eed%26companyName%3DVyome%2BHoldings%2BInc.%26formType%3D8-K%26formDescription%3DCurrent%2Breport%2Bpursuant%2Bto%2BSection%2B13%2Bor%2B15%2528d%2529%26dateFiled%3D2026-01-28&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=https%3A%2F%2Fapp.quotemedia.com%2Fdata%2FdownloadFiling%3FwebmasterId%3D90423%26amp%3Bref%3D319729142%26amp%3Btype%3DPDF%26amp%3Bsymbol%3DHIND%26amp%3Bcdn%3D69f2aca7026c215c37a8f7f436bb8eed%26amp%3BcompanyName%3DVyome%2BHoldings%2BInc.%26amp%3BformType%3D8-K%26amp%3BformDescription%3DCurrent%2Breport%2Bpursuant%2Bto%2BSection%2B13%2Bor%2B15%2528d%2529%26amp%3BdateFiled%3D2026-01-28&amp;index=9&amp;md5=f71783f2133d6a9a7a0354e6a479e7d4\">https:\/\/app.quotemedia.com\/data\/downloadFiling?webmasterId=90423&amp;ref=319729142&amp;type=PDF&amp;symbol=HIND&amp;cdn=69f2aca7026c215c37a8f7f436bb8eed&amp;companyName=Vyome+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2026-01-28<\/a><\/i><\/p>\n<p><b>About Vyome Holdings, Inc.<\/b><\/p>\n<p>\nVyome is building the world\u2019s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome\u2019s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vyometx.com&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=www.vyometx.com&amp;index=10&amp;md5=9fd15f083513f4331341bf366d55fd67\">www.vyometx.com<\/a><\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cshall,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201coutlook,\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome\u2019s business strategy, Vyome\u2019s future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome\u2019s current expectations and assumptions regarding Vyome\u2019s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome\u2019s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome\u2019s ability to leverage the India innovation corridor and otherwise advance VT-1908 into clinical development in a capital-efficient manner; Vyome\u2019s ability to raise capital to fund continuing operations; our ability to protect Vyome\u2019s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome\u2019s ability to develop and commercialize products and services; changes in government regulation; Vyome\u2019s ability to complete capital raising transactions; and other factors relating to Vyome\u2019s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause Vyome\u2019s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Vyome\u2019s assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.<\/p>\n<p>\nVisit us on social media:<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fvyometx%2F&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=Facebook&amp;index=11&amp;md5=b482798aae649f9693a014fd709a3fcf\">Facebook<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FVyomeInc&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=X&amp;index=12&amp;md5=80835568c191fb446d5959af8524d52f\">X<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvyome-therapeutics%2Fposts%2F%3FfeedView%3Dall&amp;esheet=54427752&amp;newsitemid=20260218057794&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=13&amp;md5=fb270c42ba52555951ef67539c79e146\">LinkedIn<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260218057794\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260218057794\/en\/<\/a><\/span><\/p>\n<p><a rel=\"nofollow\" href=\"mailto:contact@vyometx.com\">contact@vyometx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Optical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260218057794\/en\/2723512\/3\/Vyome_New_Logo_2025.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (\u201cVyome\u201d) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1. Uveitis refers to the immune-inflammation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937893","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (\u201cVyome\u201d) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1. Uveitis refers to the immune-inflammation &hellip; Continue reading &quot;Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T14:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity\",\"datePublished\":\"2026-02-18T14:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/\"},\"wordCount\":1132,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/\",\"name\":\"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-18T14:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk","og_description":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Vyome Holdings, Inc. (\u201cVyome\u201d) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1. Uveitis refers to the immune-inflammation &hellip; Continue reading \"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-18T14:03:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity","datePublished":"2026-02-18T14:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/"},"wordCount":1132,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/","name":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-18T14:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260218057794r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937893"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}